These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 31134501)

  • 1. Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity.
    Berger MG; Bourgne C
    Adv Exp Med Biol; 2019; 1139():171-185. PubMed ID: 31134501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Getting to the stem of chronic myeloid leukaemia.
    Savona M; Talpaz M
    Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.
    Shah K; Parikh S; Rawal R
    Asian Pac J Cancer Prev; 2016; 17(7):3025-33. PubMed ID: 27509925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Danisz K; Blasiak J
    Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
    Lin H; Woolfson A; Jiang X
    Methods Mol Biol; 2016; 1465():187-205. PubMed ID: 27581149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia stem cells: the root of chronic myeloid leukemia.
    Zhou H; Xu R
    Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
    Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
    Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current opinions and controversies in chronic myeloid leukaemia.
    Kishore B; Marin D
    Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.
    Valent P; Deininger M
    Leuk Lymphoma; 2008 Apr; 49(4):604-9. PubMed ID: 18398718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?
    Lewis M; Copland M; Soverini S; Sadovnik I; Bedel A; Prost S; Italiano A; Mahon FX
    Hematol Oncol; 2017 Dec; 35(4):420-423. PubMed ID: 27435333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
    Tortorella SM; Hung A; Karagiannis TC
    Antioxid Redox Signal; 2015 Jun; 22(16):1425-62. PubMed ID: 25366930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
    Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
    Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model.
    Lebecque B; Bourgne C; Vidal V; Berger MG
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.